An Informative Review on screening of COVID-19 (SARS-COVID-II)

Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute respiratory disease, named ‘coronavirus disease 2019’ (COVID-19), which threatens human health and public safety. The disease caused by SARS-CoV-2, coronavirus disease 2019 (COVID-19), presents flu-like symptoms which can become serious in high-risk individuals. During the early phase of the coronavirus (COVID-19) pandemic, design, development, validation, verification and implementation of diagnostic tests were actively conveyed by a large number of diagnostic test manufacturers. In this Review, we give an outline of the crucial role of diagnostic tests during the first world-wide indication of COVID-19. The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) and its associated coronavirus (COVID-19) pandemic has demanded rapid up scaling of in-vitro diagnostic assays to enable mass screening and testing of high-risk groups. To encounter the exponential demand in testing, there has been an expedite development of both molecular and serological assays across a superfluity of manifestos. The adjacent review discusses the current information on these modalities, including nucleic acid amplification tests, direct viral antigen tests. In the analytic stage, real-time reverse transcription-PCR (RT-PCR) assays remain the molecular test of choice for the etiologic diagnosis of SARS-CoV-2.